A chromosomal mutation is a change that affects the structure or the number of chromosomes — whole segments of DNA are lost, duplicated, inverted or moved to another chromosome, or the cell ends up with the wrong number of chromosomes altogether. Where a point mutation alters a single nucleotide, a chromosomal mutation can involve millions of base pairs and dozens of genes at once.
That difference in scale explains why chromosomal mutations produce such distinctive clinical pictures. Trisomy 21, the cause of Down syndrome, arises from one extra copy of chromosome 21 [7]. Chronic myeloid leukaemia is driven by a single translocation that fuses two genes into a constitutively active kinase. And across solid tumours, aneuploidy — an abnormal chromosome complement — is one of the most common genomic features of cancer cells [6].
For researchers, chromosomal mutations matter for two reasons: they are by completely different technologies than point mutations (cytogenetics rather than sequencing), and they are far harder to model faithfully in vitro. This article covers the types of chromosomal mutations, what causes them, how they differ from point mutations, how each class is detected, and how CRISPR-based tools are now making structural chromosome changes possible to engineer in cell lines.
In brief: Chromosomal mutations fall into two families — structural (deletion, duplication, inversion, translocation) and numerical (aneuploidy, polyploidy). They are detected by karyotyping, FISH, chromosomal microarray or long-read sequencing rather than by standard sequencing alone, and they are increasingly modelled with CRISPR-based chromosome engineering.
01
What Is a Chromosomal Mutation?
A chromosomal mutation is any alteration that changes the physical organisation or the copy number of chromosomes.
Structural chromosomal mutations rearrange the chromosome itself: a segment can be lost (deletion), gained (duplication), flipped (inversion), or exchanged with another chromosome (translocation).
Numerical chromosomal mutations change how many chromosomes a cell carries: an extra or missing chromosome (aneuploidy, such as trisomy 21), or a complete extra set of chromosomes (polyploidy).
Because chromosomes are the carriers of hundreds to thousands of genes, a chromosomal mutation typically affects many genes simultaneously. This is the fundamental distinction from a point mutation, which changes one position in the sequence and usually affects one gene product.
Human cells normally contain 46 chromosomes — 22 pairs of autosomes plus two sex chromosomes. Any deviation from that count, or any rearrangement of the segments within it, is classified as a chromosomal mutation.
02
Types of Chromosomal Mutations
Structural mutations
Deletion. A segment of a chromosome is lost. Deletions can be terminal (from the end) or interstitial (from within the chromosome). When a deletion removes genes that are required for normal development, the resulting haploinsufficiency — having only one functional copy instead of two — causes disease. Well-known examples include the deletions underlying DiGeorge syndrome and the *CFTR* deletions in cystic fibrosis families.
Duplication. A segment is copied, so the cell carries extra copies of the genes within it. Duplications provide raw material for evolution (a duplicated gene can acquire a new function) but they also cause disease by altering gene dosage.
Inversion. A segment is reversed end-to-end. Inversions are balanced — no genetic material is lost or gained — so carriers are usually healthy. The clinical importance of inversions lies in meiosis: the inverted segment cannot pair normally with its non-inverted partner, and crossover within the loop produces unbalanced gametes. Inversions are also relevant in cancer, where they can juxtapose a regulatory element with an oncogene.
Translocation A segment is transferred from one chromosome to another. Two broad classes are recognised:
| Class | What happens | Consequence |
|---|---|---|
| Reciprocal (balanced) | Two chromosomes exchange segments; no material lost | Carrier usually healthy, but offspring risk of unbalanced gametes |
| Robertsonian | Two acrocentric chromosomes fuse at the centromere | Carrier has 45 chromosomes and a risk of trisomy in offspring |
The clinical importance of translocations extends well beyond reproduction. When a translocation joins two genes into a fusion gene, it can create a constitutively active protein — the mechanism behind several leukaemias.
Numerical mutations
Aneuploidy. The cell has one or a few chromosomes too many or too few. Trisomy 21 (three copies of chromosome 21) is the most familiar example, and recent work has begun to map how the extra chromosome alters organ development, including the developing brain [7]. Monosomy (a missing chromosome) is generally less compatible with development.
Polyploidy. The cell carries an entire extra set of chromosomes. Polyploidy is common in plants and in liver cells, but in most human tissues it is abnormal and is frequently observed in tumour cells.
Summary: types of chromosomal mutations
| Category | Type | Change | Balance |
|---|---|---|---|
| Structural | Deletion | Segment lost | Unbalanced |
| Structural | Duplication | Segment copied | Unbalanced |
| Structural | Inversion | Segment reversed | Balanced |
| Structural | Translocation | Segment moved to another chromosome | Balanced (reciprocal) or unbalanced |
| Numerical | Aneuploidy | Extra or missing chromosome | Unbalanced |
| Numerical | Polyploidy | Extra whole chromosome set | Unbalanced |
03
What Causes Chromosomal Mutations?
Chromosomal mutations arise from errors in the mechanics of cell division and from DNA damage that overwhelms repair.
Errors in chromosome segregation. When chromosomes fail to separate correctly during mitosis or meiosis (nondisjunction), daughter cells receive the wrong chromosome number. This is the principal cause of aneuploidy, and the likelihood of such errors increases with maternal age.
Double-strand breaks joined incorrectly. A chromosome that suffers two breaks can be rejoined in the wrong configuration. If the two breaks are on different chromosomes, the result is a translocation; if they are on the same chromosome, the result may be an inversion or a deletion. Repair by non-homologous end joining is the pathway most often implicated, which is also why the frequency of structural rearrangements rises in cells with defective DNA repair.
Environmental and occupational exposures. Ionising radiation, certain chemotherapeutic agents and some industrial chemicals increase the frequency of chromosome breaks and rearrangements.
Inherited structural rearrangements. Balanced translocations and inversions can be transmitted through families. Carriers are typically unaffected, but their children face an increased risk of unbalanced chromosome complements.
04
Point Mutation vs Chromosomal Mutation: What Is the Difference?
The distinction comes down to scale and the methods needed to find them.
| Feature | Point mutation | Chromosomal mutation |
|---|---|---|
| Size of change | One or a few nucleotides | Kilobases to entire chromosomes |
| Genes affected | Usually one gene product | Often many genes at once |
| Examples | Substitution, single-base insertion or deletion | Deletion, duplication, inversion, translocation, aneuploidy |
| Detection | Sanger sequencing, NGS, allele-specific PCR, digital PCR | Karyotyping, FISH, chromosomal microarray, long-read sequencing |
| Resolution of standard testing | Base-level | Approximately 5–10 Mb for karyotype; down to ~50–100 kb for microarray |
| Typical diseases | Sickle cell disease, many cancer driver mutations | Trisomy 21, chronic myeloid leukaemia (translocation), DiGeorge syndrome (deletion) |
| Modelling in vitro | Base and prime editing deliver precise single-base changes | Requires chromosome engineering: large deletions, induced translocations |
A useful way to remember it: a point mutation is a typo in a sentence; a chromosomal mutation is a page torn out, duplicated, or bound into the wrong book. Both change the meaning, but the tools you need to spot them are different.
If you are looking specifically for how point mutations are defined, classified and detected, we cover that in detail in our guide to [point mutation types, detection methods and in vitro models]
05
How Are Chromosomal Mutations Detected?
Because chromosomal mutations are large, the classic methods "look at" chromosomes rather than reading sequence.
Karyotyping
Cells are arrested in metaphase, stained and photographed so that all chromosomes can be arranged in order. Karyotyping detects numerical abnormalities and large structural rearrangements, typically above roughly 5–10 Mb. It remains the standard first-line test for suspected aneuploidy and for balanced translocations, which sequencing-based methods may miss entirely.
Fluorescence in situ hybridisation (FISH)
Fluorescent probes bind to specific DNA sequences, allowing a defined locus to be visualised and counted in interphase or metaphase cells [1]. FISH is faster than karyotyping and can be targeted to a single gene or region, which makes it valuable for confirming a suspected fusion or a specific deletion.
Chromosomal microarray (CMA)
Array-based comparative hybridisation measures copy number across the genome at much finer resolution than karyotyping. In prenatal testing, CMA detects clinically significant copy-number changes that a karyotype would miss and has become a standard tool for investigating developmental delay and congenital anomalies [2]. Its limitation is that it detects copy number, not balanced rearrangements — an inversion or balanced translocation produces no signal change.
Long-read sequencing
Long-read platforms generate reads that span repetitive regions and breakpoints, which makes them capable of resolving structural variants at base-pair resolution — including the exact breakpoints of deletions, inversions and translocations that are invisible to short-read sequencing. Long-read approaches are being adopted in rare-disease diagnostics precisely because they can characterise structural variants that other methods only flag as "abnormal" [3].
Choosing a detection method
| Method | Detects | Resolution | Balanced rearrangements | Best for |
|---|---|---|---|---|
| Karyotyping | Numerical + large structural | ~5–10 Mb | Yes | Aneuploidy, suspected translocation |
| FISH | Targeted locus or fusion | Probe-dependent | Yes (targeted) | Confirming a known fusion or deletion |
| Chromosomal microarray | Copy number changes genome-wide | ~50–100 kb | No | Developmental delay, prenatal copy-number testing |
| Long-read sequencing | Structural variants with breakpoints | Base-pair | Yes (with breakpoint resolution) | Breakpoint mapping, cryptic rearrangements |
06
Chromosomal Mutations in Disease
Trisomy 21. One extra copy of chromosome 21 causes Down syndrome, the most common autosomal trisomy compatible with survival. The extra chromosome alters gene dosage across hundreds of genes; recent work has dissected how this changes brain development, identifying specific cell types and developmental windows that are affected [7].
Translocation-driven leukaemia. The Philadelphia chromosome — a reciprocal translocation between chromosomes 9 and 22 — creates the *BCR-ABL1* fusion and a constitutively active tyrosine kinase. Because the fusion is the driving lesion, it is also the therapeutic target, which is why translocation genotyping is central to leukaemia management.
Aneuploidy in cancer. Most solid tumours are aneuploid, and the pattern of gains and losses is not random: specific chromosomes are preferentially gained or lost in particular tumour types. Systematic genomic and functional studies have shown that aneuploidy can both promote and restrain tumour growth, depending on which chromosomes are affected [6].
Balanced rearrangements and reproduction. Because balanced inversions and translocations do not change gene dosage, carriers are usually healthy — the clinical impact appears in the next generation, as an increased risk of miscarriage or of an unbalanced chromosome complement in offspring.
07
Modelling Chromosomal Abnormalities with CRISPR
Faithfully modelling a chromosome-scale change used to be impractical in human cell lines. CRISPR-based chromosome engineering has changed that, and three capabilities are now established.
Large genomic deletions. Programmed cutting at two sites, or the use of nucleases that remove large fragments, allows defined multi-kilobase to megabase deletions to be introduced into human cells — enabling loss-of-function studies of chromosome segments rather than single genes [4].
Defined translocations. Combining CRISPR cutting with subsequent repair can generate specific chromosomal translocations in human cells. This has been demonstrated for loci relevant to haematological malignancy, allowing fusion-gene biology and its drug sensitivity to be studied in a controlled isogenic background [5].
Numerical changes and chromosome instability. Engineering aneuploidy is less straightforward, but cell models that recapitulate particular chromosome gains or losses can be derived using selection strategies after editing, complementing the classical approach of studying patient-derived lines.
What this means for study design
| Research question | Recommended approach |
|---|---|
| Does loss of a chromosomal region cause the phenotype? | CRISPR-engineered large deletion in a defined cell line |
| Does a specific fusion gene drive transformation? | CRISPR-induced translocation; validate fusion transcript by sequencing |
| Is a patient phenotype caused by a copy-number change? | Patient-derived cells plus a CRISPR-engineered isogenic copy-number control |
| How does aneuploidy affect drug response? | Aneuploid cell models (patient-derived or engineered) with karyotype confirmation |
| Is the variant a point change or a structural change? | Sequencing first; if negative, karyotype/FISH/long-read to exclude structural events |
08
Custom Cell Model Services for Structural and Sequence Variants
Whether your variant of interest is a single-base change or a chromosome-scale rearrangement, the experimental requirement is the same: a validated cell model with an appropriate isogenic control.
EDITGENE provides:
Point mutation cell lines — precise single-base changes introduced at the endogenous locus using base editing, prime editing or Cas9-mediated homology-directed repair
Large-deletion and chromosome-engineering projects — designed and validated by junction PCR and sequencing
Isogenic controls — parental and, where required, corrected lines for direct comparison
Validation package — Sanger sequencing, karyotype confirmation where relevant, and protein-level checks
10
Frequently Asked Questions
1. What is a chromosomal mutation?
A chromosomal mutation is a change in the structure or number of chromosomes — such as a deletion, duplication, inversion, translocation, or an abnormal chromosome count (aneuploidy) — rather than a change in the DNA sequence at a single position.
2. What are the types of chromosomal mutations?
Structural types are deletion, duplication, inversion and translocation; numerical types are aneuploidy (extra or missing chromosomes) and polyploidy (extra chromosome sets).
3. What is the difference between a point mutation and a chromosomal mutation?
A point mutation changes one or a few nucleotides and affects a single gene product; it is detected by sequencing. A chromosomal mutation changes the structure or number of chromosomes, affects many genes at once, and is detected by karyotyping, FISH, chromosomal microarray or long-read sequencing.
4. Can a chromosomal mutation be detected by DNA sequencing alone?
Not reliably. Standard short-read sequencing is poor at resolving large structural rearrangements and is completely blind to balanced translocations. Karyotyping, FISH or long-read sequencing are needed for those.
5. What causes chromosomal mutations?
Nondisjunction during meiosis or mitosis (leading to aneuploidy), incorrectly repaired double-strand breaks (leading to translocations, inversions and deletions), ionising radiation and certain chemicals, and inherited balanced rearrangements.
6. Are chromosomal mutations inherited?
They can be. Balanced translocations and inversions are often inherited from an unaffected carrier parent, with the clinical risk appearing as an increased chance of unbalanced chromosomes in offspring.
7. Which chromosomes are most commonly involved in aneuploidy?
Trisomy 21, 18 and 13 are the autosomal trisomies most compatible with survival, and sex chromosome aneuploidies (such as 45,X and 47,XXY) are also relatively common. Most other autosomal trisomies are not compatible with development.
8. What is the difference between a balanced and an unbalanced translocation?
A balanced translocation exchanges material without loss or gain, so the carrier is usually healthy. An unbalanced translocation results in extra or missing material, which causes developmental and clinical consequences.
9. Can chromosomal mutations be modelled in cell lines?
Yes. CRISPR-based chromosome engineering can introduce defined large deletions and specific translocations in human cells, and aneuploid models can be derived by selection or from patient material with karyotype confirmation.
10. How do I know whether to test for a point mutation or a chromosomal mutation?
Start from the clinical or research question. If a single-gene mechanism is suspected (a specific missense variant, for example), sequence first. If the phenotype suggests a syndrome with multiple affected genes, or a leukaemia with a suspected fusion, go straight to cytogenetic and structural-variant testing.
11
Conclusion
Chromosomal mutations operate at a different scale from point mutations: they rearrange or miscount the chromosomes themselves, affect many genes at once, and require cytogenetic and structural-variant methods — karyotyping, FISH, microarray and long-read sequencing — to detect. Understanding the six main types, their causes, and their detection limits is essential for interpreting a test result correctly, especially when a balanced rearrangement is invisible to the assay being used.
The practical challenge is modelling them. With CRISPR-based chromosome engineering, defined large deletions and specific translocations are now achievable in human cell lines, which brings structural variants into the same experimental framework as point mutations: build the change, confirm it at the sequence or junction level, and compare against an isogenic control.
For the sequence-level counterpart of this topic, see our guide to [point mutation: three types, detection methods and in vitro models](/blog/point-mutation-types-detection-in-vitro-models).
References
[1] McNeil JA, Johnson CV, Carter KC, Singer RH, et al. (1991). Localizing DNA and RNA within nuclei and chromosomes by fluorescence in situ hybridization. Genetic Analysis, Techniques and Applications 8(2):41–58. PMID: 1712212. DOI: 10.1016/1050-3862(91)90049-w
[2] Levy B, Wapner R. (2018). Prenatal diagnosis by chromosomal microarray analysis. Fertility and Sterility 109(2):201–212. PMID: 29447663. DOI: 10.1016/j.fertnstert.2018.01.005
[3] Moustakli E, Christopoulos P, Potiris A, Zikopoulos A, et al. (2025). Long-Read Sequencing and Structural Variant Detection: Unlocking the Hidden Genome in Rare Genetic Disorders. Diagnostics 15(14):1803. PMID: 40722552. DOI: 10.3390/diagnostics15141803
[4] Hou Z, Hu C, Ke A, Zhang Y. (2022). Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3. Current Protocols 2(2):e361. PMID: 35129865. DOI: 10.1002/cpz1.361
[5] Azami Y, Tsuyama N, Abe Y, Sugai-Takahashi M, et al. (2021). Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells. Scientific Reports 11(1):5216. PMID: 33664418. DOI: 10.1038/s41598-021-84628-5
[6] Taylor AM, Shih J, Ha G, Gao GF, et al. (2018). Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4):676–689.e3. PMID: 29622463. DOI: 10.1016/j.ccell.2018.03.007
[7] Russo ML, Sousa AMM, Bhattacharyya A. (2024). Consequences of trisomy 21 for brain development in Down syndrome. Nature Reviews Neuroscience 25(11):740–755. PMID: 39379691. DOI: 10.1038/s41583-024-00866-2
[8] 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, et al. (2015). A global reference for human genetic variation. Nature 526(7571):68–74. PMID: 26432245. DOI: 10.1038/nature15393
